1/14
07:06 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/10
07:02 pm
glue
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum [Yahoo! Finance]
Medium
Report
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum [Yahoo! Finance]
1/9
02:22 am
glue
Monte Rosa Therapeutics announces pricing of $300M stock offering [Seeking Alpha]
Medium
Report
Monte Rosa Therapeutics announces pricing of $300M stock offering [Seeking Alpha]
1/8
10:49 pm
glue
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Medium
Report
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
1/8
10:24 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $22.00 to $30.00. They now have an "overweight" rating on the stock.
Low
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $22.00 to $30.00. They now have an "overweight" rating on the stock.
1/8
09:02 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Guggenheim from $16.00 to $34.00. They now have a "buy" rating on the stock.
Medium
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Guggenheim from $16.00 to $34.00. They now have a "buy" rating on the stock.
1/8
08:08 am
glue
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation [Seeking Alpha]
Medium
Report
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation [Seeking Alpha]
1/8
06:15 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
High
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/7
05:01 pm
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/7
04:17 pm
glue
Monte Rosa Therapeutics launches $200M public equity offering [Seeking Alpha]
High
Report
Monte Rosa Therapeutics launches $200M public equity offering [Seeking Alpha]
1/7
04:01 pm
glue
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
High
Report
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
1/7
03:02 pm
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
1/7
02:56 pm
glue
Top Midday Gainers [Yahoo! Finance]
Low
Report
Top Midday Gainers [Yahoo! Finance]
1/7
01:51 pm
glue
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]
1/7
11:03 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "outperform" rating reaffirmed by analysts at Wedbush.
Medium
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "outperform" rating reaffirmed by analysts at Wedbush.
1/7
07:00 am
glue
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
High
Report
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
1/6
04:05 pm
glue
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
High
Report
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
12/17
07:06 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
High
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/16
07:10 am
glue
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations [Yahoo! Finance]
12/16
07:00 am
glue
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
Medium
Report
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
12/15
04:15 pm
glue
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results [Yahoo! Finance]
High
Report
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results [Yahoo! Finance]
12/15
04:01 pm
glue
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
High
Report
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
12/11
02:10 pm
glue
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn [Yahoo! Finance]
Low
Report
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn [Yahoo! Finance]
12/11
04:18 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/30
04:41 am
glue
Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]
Medium
Report
Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]